ALNY ALNYLAM PHARMACEUTICALS INC

2026Q1 · CUSIP 02043Q107 · Sector: Healthcare & Biotech

Danger · Dual-confirm: breadth + price

Holders

779

Δ holders QoQ

-67

Breadth percentile

Top 98%

Whale holders

286

Δ whales

-8

Inst. holding value

$40.4B

New positions

102

Closed positions

169

Price momentum (1Q)

-13.9%

Put / Call

17/17

Breadth history (34 quarters)

Period	Percentile	Next-1Q return	Next-2Q return
2025Q4	Top 17%	-13.9%	—
2025Q3	Top 1%	-26.3%	-35.2%
2025Q2	Top 11%	-1.7%	-27.2%
2025Q1	Top 6%	+57.0%	+57.8%
2024Q4	Top 16%	+16.7%	+83.3%
2024Q3	Top 6%	+7.9%	+24.4%
2024Q2	Top 8%	-3.9%	-6.6%
2023Q4	Top 10%	+1.6%	+86.7%
2022Q3	Top 0%	+5.1%	-10.0%
2021Q4	Top 17%	-16.3%	+45.8%
2020Q2	Top 6%	-3.7%	+11.3%
2020Q1	Top 7%	-2.9%	-6.5%
2019Q4	Top 13%	+12.6%	+9.3%
2018Q1	Top 15%	-8.5%	-36.0%

Show all 14 events

Put holders

QoQ: -6

Call holders

QoQ: -4

See methodology →

PE (TTM)

120.7

EPS (TTM)

$2.33

EPS YoY

—

Revenue (TTM)

$3.7B

Revenue YoY

+65.2%

Quarterly Revenue & EPS (4Y)

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2025-12-31 · SEC filings (XBRL)